LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).

Barbara Burtness, Robert I. Haddad, José Dinis et al.|Journal of Clinical Oncology|2017

Cited by 13